PBYIHealthcare · BiotechnologyThe 1 Wall Street analysts covering Puma Biotechnology, Inc. hold a median 12-month price target of $6 — -39.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 8 Oct 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Puma Biotechnology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (99): The shares have been drifting up relative to others.
Revisions (25): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PBYI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −39.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | TD Cowen | Maintains | Hold | $5.00 → $6.00 |
| 28 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | $7.00 |
| 28 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 23 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Feb 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Sept 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 June 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Mar 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 Aug 2022 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PBYI appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Puma Biotechnology, Inc. returned +90.6% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 39% of US stocks
Cheaper than 50% of US stocks
Cheaper than 28% of US stocks
Cheaper than 38% of US stocks
Higher than 46% of US stocks
Higher than 71% of US stocks
Higher than 89% of US stocks
Higher than 70% of US stocks
Higher than 73% of US stocks
Higher than 83% of US stocks
Higher than 92% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Puma Biotechnology, Inc. has a market value of $490.4M and an enterprise value of $401.3M.
Revenue in the twelve months to 30 June 2026: $231.2M. The latest quarter grew 7.8% year on year.
Net income over the same four quarters: $26.7M, a 11.6% net margin.
Diluted earnings per share, trailing twelve months: $0.52.
Free cash flow in the twelve months to 30 June 2026: $41.2M.
Trailing P/E: 18.6×; forward P/E: 27.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Puma Biotechnology, Inc. employs 179 people — $1.3M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Puma Biotechnology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Puma Biotechnology announced that it granted an inducement award to one new hire in September 2026, as required under Nasdaq Listing Rule 5635(c)(4). The company made the announcement in a press release on Business Wire.
Why it matters — PBYI watchers may track this as a standard corporate-governance disclosure tied to hiring and stock-based compensation practices.
Puma Biotechnology has begun the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.
Why it matters — The initiation of this phase II trial signals progress in Puma's clinical pipeline for alisertib as a combination therapy in small cell lung cancer.
Puma Biotechnology has initiated ALISCA®-Lung2, a Phase II trial evaluating alisertib in combination with paclitaxel for patients with advanced small cell lung cancer. The trial's launch marks a new development milestone for the company's pipeline.
Why it matters — A PBYI watcher would care because this new Phase II trial expands the company's clinical pipeline and advances its investigational drug alisertib toward potential new applications.
Puma Biotechnology announced that CEO Alan Auerbach will present a corporate overview at H.C. Wainwright's 28th Annual Global Investment Conference on September 14, 2026. The presentation was disclosed via a Business Wire statement from Los Angeles.
Why it matters — A PBYI watcher would note that the CEO's scheduled presentation gives investors an opportunity to hear a corporate overview from company leadership at a major investment conference.
Puma Biotechnology's NERLYNX provides an established revenue stream that could support the development of alisertib into a potential second oncology franchise. The company currently has positive cash flows and a healthy balance sheet, while alisertib remains a speculative Phase 2 asset whose biomarker strategy may help identify responsive patients.
Why it matters — A PBYI watcher would care because NERLYNX's cash flow may fund the company's next potential oncology franchise in alisertib, though that candidate is still early-stage and speculative.
The 1 Wall Street analysts covering Puma Biotechnology, Inc. have a median 12-month price target of $6, with estimates ranging from $6 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Puma Biotechnology, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Puma Biotechnology, Inc. 92 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Puma Biotechnology, Inc. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies -39.8% from the last close, and Ticker Nerd's factor model ranks Puma Biotechnology, Inc. 92 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Puma Biotechnology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PBYI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $6 over the next 12 months.
Puma Biotechnology, Inc. returned +90.6% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing therapies that support cancer care.
The most recent item we track (Business Wire, 5 Oct 2026): "Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)". Puma Biotechnology announced that it granted an inducement award to one new hire in September 2026, as required under Nasdaq Listing Rule 5635(c)(4). The company made the announcement in a press release on Business Wire.
Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing therapies that support cancer care. Its current portfolio centers on NERLYNX, an oral treatment based on neratinib used in specific HER2-positive breast cancer settings, along with alisertib, an investigational oncology candidate being studied across several tumor types. The company works through specialty pharmacy and distributor networks and maintains licensing and collaboration agreements that support the development, manufacture, and commercialization of its cancer-focused products. Puma Biotechnology serves patients and healthcare providers in the United States and select international markets, with an emphasis on targeted therapies for oncology. Based in Los Angeles, California, Puma Biotechnology plays a specialized role in the biotechnology market by concentrating on molecularly targeted cancer treatments and late-stage product commercialization.
CEO Mr. Alan H. Auerbach · 179 employees · United States · https://www.pumabiotechnology.com
